^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Excerpt:
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with a deleterious BRCA mutation
(germline and/or somatic)-associated epithelial ovarian, fallopian tube, or
primary peritoneal cancer who have been treated with two or more
chemotherapies.
Source:
Title:
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Excerpt:
...- Solid tumor, advanced or metastatic, progressed on standard treatment participants in Arm B must have either triple negative breast cancer OR urothelial carcinoma OR ovarian cancer OR have a solid tumor with a deleterious mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D...
Trial ID:
Source:
Title:
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
Published date:
03/22/2021
Excerpt:
Patients with TNBC or deleterious BRCA mutation (TNBC/BRCAmut)...In the high-risk post preoperative TNBC/BRCAmut setting, the addition of low-dose rucaparib did not improve 2-year DFS or increase the toxicity of cisplatin...
Secondary therapy:
cisplatin
DOI:
10.1038/s41523-021-00240-w
